Cue Biopharma (NASDAQ: CUE) experienced a dramatic surge in its stock price on Friday morning, following a series of significant corporate developments. The Boston-based biotechnology firm saw its shares jump 91.4% to $28.21 as of 11:03 a.m. EDT, after closing at $14.74 the previous day. The stock opened at $33.75 before retreating somewhat.
Key Announcements Drive Rally
The rally was fueled by three major announcements: the licensing of a Phase 2 anti-IgE antibody, the appointment of a new chief executive officer, and a $30 million private placement. The company is aggressively pivoting toward clinical-stage immunology assets after a challenging period for its stock, which recently underwent a 1-for-30 reverse stock split to comply with Nasdaq's minimum bid price rule.
Allergy Drug Deal Details
Cue Biopharma has entered into a licensing agreement with Ascendant Health Sciences for Ascendant-221, a monoclonal antibody targeting immunoglobulin E (IgE), a key driver of allergic responses. The deal grants Cue global rights to the drug outside of greater China, which includes mainland China, Hong Kong, Macau, and Taiwan. Under the terms, Cue will pay $15 million upfront and could owe up to $676.5 million in milestone payments, along with tiered royalties on future sales.
The antibody is currently being evaluated in a Phase 2 trial in China for chronic spontaneous urticaria, a condition characterized by recurrent hives. Data from this study is expected in the second half of 2026. Cue plans to initiate a global Phase 2b trial for food allergy after reviewing the urticaria results. This move positions Cue in a competitive landscape where Novartis recently acquired Excellergy for up to $2 billion to bolster its allergy portfolio, and where Roche and Novartis already market Xolair, an anti-IgE therapy approved for food allergies.
New CEO Takes the Helm
Shao-Lee Lin has been appointed as Cue's president, CEO, and board director, succeeding interim CEO Lucinda Warren. Lin brings extensive experience, having founded ACELYRIN and held senior roles at Horizon Therapeutics, AbbVie, Gilead Sciences, and Amgen. In a statement, Lin expressed enthusiasm for leading Cue's pipeline, including CUE-401 and the newly licensed program. Board chairman Pasha Sarraf highlighted Lin's "disciplined approach" as a key asset for advancing the company's clinical pipeline.
Million Private Placement
Cue Biopharma has secured approximately $30 million in gross proceeds through a private investment in public equity (PIPE) deal. The company is selling pre-funded warrants for up to 2,727,272 common shares, along with warrants for an additional 1,363,636 shares, at an effective price of $11 per pre-funded warrant and its accompanying warrant. After fees to placement agent Newbridge Securities, net proceeds are expected to be around $28 million. Notably, Shao-Lee Lin is among the investors participating in the offering.
Market Context and Risks
The biotech sector has shown renewed interest in IgE-targeting therapies, with Novartis's recent acquisition underscoring the potential of this approach. Xolair's FDA approval in 2024 as the first drug to reduce allergic reactions to multiple foods has set a high bar. Cue's Ascendant-221 aims to differentiate itself by offering more durable suppression of free IgE, potentially enabling less frequent dosing. However, these claims remain unproven in larger trials.
Cue Biopharma faces significant risks, including the need for shareholder approval for the warrants, thin cash reserves, a history of operating losses, going-concern doubts, and reliance on partners. The success of Ascendant-221 hinges on positive clinical data from the China urticaria study and subsequent global trials. Any disappointing results could derail the company's plans.
